Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients.
In cystic fibrosis (CF), pancreatic insufficiency and a diminished bile acid pool cause malabsorption of important nutrients and dietary components leading to deficiency, poor nutritional status, and oxidative stress. Of particular significance is the malabsorption of fat-soluble nutrients and antioxidants, which are important for normal immune and neurologic function. Patients with CF often are deficient in these compounds despite supplementation with the current standard of care therapy. The objective was to compare the pharmacokinetic profile of this water-soluble vitamin E formulation (Aqua-E) with an oil-based softgel formulation in a malabsorbing patient population. Patients with CF who had documented malabsorption were recruited for participation in this pharmacokinetic study. Patients who met inclusion and exclusion criteria discontinued vitamin E supplementation, except for that in a multivitamin, for 7 to 21 days before the day of dosing. Patients were randomized to a single dose of 20 ml of Aqua-E or three oil-based softgels, which contained equivalent amounts of tocopherols. Blood was drawn from patients at time 0, 2, 4, 8, 24, 48, and 168 hr and analyzed for tocopherols. Eight patients were enrolled in the study and randomized to Aqua-E or softgels. The primary outcome, the absorption of gamma-tocopherol in Aqua-E (AUC=115 micro g/ml(*)hr), was significantly greater than that of oil-based softgels (AUC=25.3 micro g/ml(*)hr; P=0.013). Total-tocopherols (alpha+gamma+delta) in Aqua-E (AUC=294 micro g/ml(*)hr) showed a strong trend toward increased absorption compared with that of oil-based softgels (AUC=117 micro g/ml(*)hr; P=0.09). In conclusion, this novel, water-soluble formulation showed a marked and statistically significant increase in absorption of gamma-tocopherol in malabsorbing patients with CF compared with an oil-based formulation.
Papas
Konstantinos
K
Yasoo Health Inc, Johnson City, TN 37604, USA. kpapas@yasoo.com
Kalbfleisch
John
J
Mohon
Ricky
R
D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000737:chemistry / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications; D004304:Dosage Forms; D006801:Humans; D007408:Intestinal Absorption; D008055:Lipids / Q000737:chemistry; D008286:Malabsorption Syndromes / Q000209:etiology / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000493:pharmacokinetics; D012995:Solubility; D012997:Solvents / Q000737:chemistry; D024505:Tocopherols / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D014810:Vitamin E / Q000031:analogs & derivatives / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D014867:Water / Q000737:chemistry; D024502:alpha-Tocopherol / Q000493:pharmacokinetics; D024504:gamma-Tocopherol / Q000493:pharmacokinetics
D000975:Antioxidants; D004304:Dosage Forms; D008055:Lipids; D012997:Solvents; D014867:Water; D014810:Vitamin E; D011092:Polyethylene Glycols; D024504:gamma-Tocopherol; D024502:alpha-Tocopherol; C479072:delta-tocopherol; C014225:tocophersolan; D024505:Tocopherols